Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase  by Ishiura, Shoichi et al.
Volume 260, number 1, 131-134 FEB 08029 January 1990 
Identification of a putative amyloid A4-generating enzyme as a prolyl 
endopeptidase 
Shoichi Ishiura, Toshifumi Tsukahara, Takeshi Tabira, Teruo Shimizu, Kiichi Arahata and Hideo Sugita 
National Institute of Neuroscience, NCNP, Kodaira, Tokyo 187, Japan 
Received 26 September 1989; revised version received 27 November 1989 
The A4 amyloid peptide is deposited in Alzheimer’s disease inside neurons as neurofibrillary tangles or extracellularly as vascular amyloid. The 
A4 peptide is cleaved off by an unidentified proteinase from a larger precursor protein (APP), which resembles acell surface receptor. The protein- 
ase, which cleaves off the membrane-spanning domain of APP, may be important in amyloid formation. To evaluate this, a model peptide substrate, 
succinyl- isoleucyl-alanine-methylcoumarinamide, which is homologous to the C-terminal portion of A4 peptide, was synthesized to screen the 
putative A4-generating proteinase. On chromatographic purification, ii was found that two proteinases are involved in the hydrolysis of the peptide, 
the major one being identified as a prolyl endopeptidase. This evidence may facilitate elucidation of the mechanism of amyloid deposition in 
Alzheimer’s disease. 
Amyloid; A4 peptide; Prolyl endopeptidase; Alzheimer’s disease; (Rat brain) 
1. INTRODUCTION 2. MATERIALS AND METHODS 
In Alzheimer’s disease (AD), the amyloid A4 peptide 
is thought to arise from its precursor protein (APP) 
with deposition in brain tissue [l-3]. We therefore used 
rat brain to purify the ACgenerating proteinase. The 
A4 peptide is the small C-terminal portion of APP, and 
includes part of the putative membrane-spanning 
region and part of the adjacent exfracellular domain. 
A4 isolated from both amyloid plaque cores and 
neurofibrillary tangles shows N-terminal heterogeneity, 
indicating the involvement of several proteinases in its 
production. Considering its self-aggregating property, 
liberation of the A4 peptide from APP should occur 
after splitting of the N-terminal extracellular domain, 
excretion of the latter into the serum [4,5] and the 
following essential cleavage of the transmembrane do- 
main. Initial cleavage of the transmembrane domain 
cannot occur in vivo. The fact that an APP lacking 
only the C-terminal 55-60 amino acids has never been 
found in serum confirms the above assumption. 
To screen the putative ACgenerating proteinase, we 
synthesized a model peptide homologous to the C- 
terminal portion of A4 peptide. Purification from rat 
brain revealed that the peptide was efficiently cleaved 
by an endogenous proteinase, identified as a prolyl en- 
dopeptidase. 
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science, NCNP, Kodaira, Tokyo 187, Japan 
2.1. Materials 
The model peptide, succinyl-isoleucyl-alanine-methylcoumari- 
namide (SIA-MCA) was synthesized by Peptide Inst. Co., Minoh, 
Osaka, Japan. The other peptides were also obtained from the same 
company. The specific inhibitor of prolyl endopeptidase, Z-thiopro- 
thiazolidine, was kindly provided by Dr Tadashi Yoshimoto, 
Nagasaki University. 
2.2. Assay method 
Our standard assay conditions were as follows: enzyme samples 
were mixed with a peptide substrate (final concentration: 0.1 mM), 
in a total volume of 0.1 ml, in 50 mM Tris-HCl, pH 7.0, containing 
10 mM 2-mercaptoethanol. After incubation at 37°C for 30 min. the 
reaction was terminated by the addition of 0.1 ml of 10% sodium 
dodecyl sulfate and 1.3 ml of 0.2 M Tris-HCI, pH 9.0 [6,7]. The 
aminomethylcoumarin liberated was determined with a Hitachi 
fluorescent spectrophotometer F-3000 (ex. 380 nm; em. 460 nm). 
3. RESULTS AND DISCUSSION 
Fig. 1 shows the purification of the A4-generating en- 
zyme. DEAE-cellulose chromatography revealed the 
presence of two enzymes responsible for the degrada- 
tion of a model peptide, succinyl-isoleucyl-alanine- 
methylcoumarin-amide (Sue-Ile-Ala-MCA or SIA- 
MCA). The major one, eluted at 0.10 M NaCl, was 
concentrated and applied to the next column. We also 
purified the minor one, eluted at 0.18 M NaCl, to 
homogeneity. The latter enzyme had different 
characteristics from the major ACgenerating one [8]. 
The major active fraction was further purified on 
hydroxyapatite, gel filtration, heparin-Sepharose and 
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Fig. 1. DEAE-cellulose chromatography profile of the succinyl- 
isoleucyl-alanine-methylcoumarinamide @IA-MCA) degrading 
proteinase. Rat brain (23.5 g) was homogenized with 5 vols of 5 mM 
phosphate00 mM 2-mercaptoethanol, pH 7.0 {buffer A), in a glass 
homogenizer, and then the homogenate was centrifuged at 10000 x 
g for 10 min. The clear supernatant was directly applied to a 200 ml 
DEAE-cellulose column equilibrated with buffer A. After washing, 
the column was eluted with a linear NaCl gradient (O-O.5 M; total, 
1600 ml) at 4°C. 20 ml fractions were collected and assayed for SIA- 
MCA degrading activity. (-) Protein absorbance at 280 nm; 
(o---o) enzymatic activity, measured as the liberation of 
aminomethylcoumarin (FU, fluorescence unit) after 30 min. 1 FU 
approximately corresponds to 1 nmol AMClh under our standard 
assay conditions. 
benzamidine-Sepharose coiumns (fig.%). SIA-MCA 
degrading activity was adsorbed to p- 
aminobenzamidine-Sepharose and eluted at 0.1 N 
NaCI, with an almost 100% activity recovery. The pro- 
tein with SIA-MCA hydrolyzing activity eluted from 
the column gave a single band under nondenaturing 
conditions. On HPLC gel filtration on TSKG3000 SW, 
the native molecular mass was estimated to be 110000. 
When electrophoresed on polyacrylamide in the 
presence of SDS under reducing conditions, one band 
appeared. It corresponded to 72000 as judged on com- 
parison with molecular markers. 
The rates of hydrolysis of the methylcoumarin~ides 
of 8 synthetic peptides are shown in table 1. Surprising- 
ly, the purified enzyme most efficiently cleaved Suc- 
Gly-Pro-Leu-Gly-Pro-MCA (SGPLGP-MCA), the 
substrate of prolyl endopeptidase (PEPase) [9,10], in 
the presence of 2-mercaptoethanol. We reassayed every 
chromatographic fraction for PEPase activity and 
found that Sue-Gly-Pro-Leu-Gly-Pro-MCA degrading 
activity coincided with Sue-Ile-Ala-MCA degrading ac- 
tivity, except for the minor peak of SIA-MCA 
hydrolyzing activity observed on DEAE-cellulose 
chromatography (see fig.1). No other PEPase activity 
was observed in subsequent chromatographies. The 
other substrates, such as Sue-Ala-Ala-Ala-MCA and 
Sue-Ala-Pro-Ala-MCA, were moderately digested by 
the purified enzyme, but the rates of hydrolysis were 
below 1130. These characteristics are similar to those of 
PEPase from Flavobacterium 111,121 and bovine brain 
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Fig.2. Final benzamidine-Sepharose column chromatography of 
putative A4-generating proteinase. The active fractions (fractions 
26-30 in fig. 1) were dialyzed against buffer A overnight and then 
applied to a 20 ml hydroxyapatite column ~uilibrat~ with the same 
buffer. The enzyme was adsorbed to the column and eluted with a 
linear phosphate gradient (O-300 mM; total, 400 ml). The peak of 
SIA-MCA degrading activity was eluted immediately after the 
application of the gradient, which separated a contaminating minor 
activity (see fig. 1, fractions 35-45) from the major peak. The activity 
peak fractions were concentrated and applied to an analytical HPLC 
gel filtration column (TSKG3000 SW, 0.75 x 60 cm). The SIA-MCA 
hydrolytic activity was eluted as a single symmetrical peak 
corresponding to a molecular mass of 110000. Fractions containing 
the active enzyme were collected, again dialyzed against buffer A and 
then directly applied to a heparin-Sepharose column. Half the 
contaminating proteins were effectively removed by passage through 
this column. The SIA-MCA degrading activity was recovered in the 
flow-through fraction. Affinity isolation of the SIA-MCA degrading 
enzyme on p-aminobenzamidine-Sepharose was conducted at room 
temperature. The filtered enzyme samples were collected and applied 
to a 1 ml inhibitor column equilibrated with buffer A. After all the 
samples had been passed through the column, the unadsorbed protein 
was removed by washing with 10 bed vols of buffer A, and then the 
column was eluted with 5 bed vols of buffer A containing 0.1 M NaCl 
(arrow). The eluted sample was collected on ice. The eluate could be 
stored for a week at 4°C without significant loss of activity. (-) 
Protein absorbance at 280 nm; (0) enzyme activity. 
[ 131. The rate of hydrolysis was almost zero when a 
trypsin substrate, which had an arginyl or lysyl residue 
as the residue immediately Gino-terming to the scissi- 
ble bond (at Pl), was used for the assay. In addition, 
Phe at the Pl site was not accessible to the enzyme. 
The rate of hydrolysis of the substrate for PEPase 
was enhanced in the presence of an SH-compound. In 
the case of SGPLGP-MCA, the hydrolysis was increas- 
ed 40-fold. The results indicate that the enzyme has an 
essential SH group at or near the active site, although 
it is not a cysteine proteinase because a specific cysteine 
proteinase inhibitor, E-64 [14,15], did not inhibit the 
peptide hydrolysis at all, The SIA-MCA and SGPLGP- 
MCA degrading activities of the purified sample were 
both strongly inhibited on the addition of the PEPase- 
specific inhibitor, Z-thiopro-thiazolidine [16] (see also 
table 2). About 70% of both activities was inhibited by 
100 nM of the inhibitor. The results strongly suggest 
that the SIA-MCA degrading proteinase is a tissue pro- 
lyl endopeptidase. 
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Table 1 Table 2 
Substrate specificity of the purified enzyme Effects of proteinase inhibitors on the PEPase activity of the purified 
enzyme 
Substrate Activity (nmol/h) Activation 
(-fold) 
- 2ME + 2ME 
Sue-Be-Ala-MCA 0.062 0.923 14.9 
Sue-Gly-Pro-Leu-Gly-Pro-MCA 8.46 339 40.1 
Sue-Ala-Ala-Ala-MCA 0.227 7.15 31.5 
Sue-Ala-Pro-Ala-MCA 0.203 10.2 50.2 
Sue-Ala-Ala-Pro-Phe-MCA 0.053 0.179 3.4 
Sue-Ala-Ala-Phe-MCA 0 0 - 
Ala-Ala-Phe-MCA 0 0 - 
Glt-Phe-MCA 0 0 - 
0.12 ~g of the enzyme was incubated with 50 mM Tris-HCI, pH 7.0, 
and 0.1 mM of each substrate for 30 min in the presence or absence 
of 2-mercaptoethanol (2ME). The activity is expressed as nmol 
aminomethylcoumarin liberated/h. Sue, succinyl; Glt, glutaryl 
Proteinase inhibitor Concentration Relative activity (W) 
SGPLGP-MCA SIA-MCA 
The gene encoding the APP produces at least 3 
mRNAs [17-191. Two of them, APP750 and APP771, 
contain an insert, which is highly homologous to the 
Kunitz-type serine proteinase inhibitor (KPI). If the in- 
hibitor domain functions as a proteinase inhibitor in 
vivo, it could either promote amyloidogenesis by in- 
hibiting the ACdegrading proteinase or inhibit 
amyloidogenesis by inhibiting the A4-generating pro- 
teinase. To investigate the specificity of the purified 
PEPase, various proteinase inhibitors were examined 
(table 2). Kunitz-type bovine pancreas trypsin inhibitor 
(BPTI) and aprotinin inhibited the rat brain enzyme, 
whereas soybean Bowman-Birk trypsin inhibitor and 
the control albumin did not. The concentration of the 
inhibitor required for inhibition was slightly higher 
than estimated. 
None - 100 100 
Kunitz BPTI 0.01 mg/ml 74 94 
0.1 mg/ml 25 30 
Soybean trypsin inhibitor 0.01 mg/ml 100 100 
0.1 mg/ml 100 100 
Aprotinin 0.01 mg/ml 91 40 
0.1 mg/ml 78 38 
Bovine serum albumin 0.01 mg/ml 107 100 
0.1 mg/ml 91 100 
Z-thiopro-thiazolidine 0.1 nM 100 99 
1 nM 92 90 
10 nM 59 61 
100 nM 24 17 
The purified enzyme was incubated with 0.1 mM SGPLGP-MCA or 
SIA-MCA, as described in the legend to table 1, in the presence of 
various types of proteinase inhibitor. Bovine serum albumin was used 
as a control 
firmed. As a working hypothesis, we propose that the 
PEPase may directly act as an amyloid ACgenerating 
proteinase in AD. 
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The activity of PEPase in the brain of 3 AD patients 
(356 f 125 nmol/h/mg) was not statistically different 
from that in 7 age-matched controls (350 f 
75 nmol/h/mg). This rules out the possibility of the 
overproduction of PEPase in AD brain. Other factors, 
such as the different expression of the 3 mRNA species 
of APP or the presence of other proteinase inhibitors 
in the amyloid deposit, may contribute to the forma- 
tion of the A4 peptide. In this connection, it would also 
be interesting to investigate the effect of 
cyr-antichymotrypsin [20], which is deposited in 
amyloid plaques, on the ACgenerating proteinase. 
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